Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

79.00GBp
4:40pm BST
Change (% chg)

0.00 (+0.00%)
Prev Close
79.00
Open
80.15
Day's High
80.45
Day's Low
78.75
Volume
375,348
Avg. Vol
764,995
52-wk High
90.15
52-wk Low
65.85

Summary

Name Age Since Current Position

Bruno Angelici

72 2014 Non-Executive Chairman of the Board

Paul Fry

2019 Interim Chief Executive Officer, Chief Financial Officer, Executive Director

Joanne Hombal

2015 Executive Vice President of Human Resources

Antony Fitzpatrick

2017 Executive Vice President – Operations

Roger Heerman

43 2014 Executive Vice President - Commercial and Business Development

David Lescuyer

2016 Executive Vice President – Oral Business

Gonzalo Miquel

2017 Chief Medical Officer & Executive Vice President - Development

Geraldine Venthoye

2016 Executive Vice President - Pharmaceutical Development Appointment

John Murphy

62 2016 General Counsel, Company Secretary

Per-Olof Andersson

65 2015 Non-Executive Director

Juliet Thompson

52 2017 Non-Executive Director

Thomas Werner

63 2016 Non-Executive Director

Susan Foden

2016 Senior Independent Non-Executive Director

Kevin Matthews

53 2019 Independent Non-Executive Director

Neil Warner

2011 Non-Executive Independent Director

Anne Whitaker

51 2018 Independent Non-Executive Director

Elizabeth Knowles

2019 IR Contact

Biographies

Name Description

Bruno Angelici

Mr. Bruno F. J. Angelici, MBA, is Non-Executive Chairman of the Board of the Company, effective 1 February 2014. He was appointed to the Board of Vectura Group on 1 December 2013 and became Non-Executive Chairman on 1 February 2014. Bruno Angelici is a French national with an MBA (Kellogg School of Management) and business and law degrees from Reims. Bruno Angelici’s career includes senior management roles in pharmaceutical and medical device companies. Bruno Angelici retired from AstraZeneca in 2010 as Executive Vice President International after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa having originally joined as President of ICI Pharma France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries. Bruno Angelici is a Non-Executive Director of Smiths Group plc, a FTSE 100 technology group, and Novo Nordisk A/S, a global healthcare company and world leader in diabetes care. He is also a member of the Global Advisory Board of Takeda Pharmaceutical Company Ltd Japan, the largest pharmaceutical company in Asia, and a member of the Supervisory Board of Wolters Kluwer NV, a global information services and publishing company.

Paul Fry

Mr. Paul Fry re-designated as Interim Chief Executive Officer, Chief Financial Officer, Executive Director of the Company., with effective 30th June 2019. Paul joins Vectura from Immunocore, the privately held leading T Cell Receptor biotechnology company, where he has been Chief Financial Officer since January 2017. Paul has significant experience in senior positions in the healthcare and telecommunications sectors. Before joining Immunocore Paul served as Director of Global Finance Operations at Vodafone Plc, where he was responsible for key financial controller activities and core processes as well as large transformation programmes. Prior to his role at Vodafone, Paul spent more than 25 years at GlaxoSmithKline (GSK), where he held a number of senior roles including Head of Global Finance Services and as CFO for GSK's Italian Pharmaceutical business. Paul graduated from Oxford University in 1988 and qualified as an accountant with the Chartered Institute of Management Accountants in 1991.

Joanne Hombal

Ms. Joanne Hombal serves as Executive Vice President of Human Resources of the Company. She joined Vectura in January 2015. Joanne has a BSc in psychology from the University of Birmingham and a postgraduate diploma in human resource management from the University of Glamorgan and is a Chartered Member of the Institute of Personnel and Development. Before joining Vectura, Joanne was vice president HR at Invensys Rail, with responsibility for setting and leading the people strategy for Northern Europe. She has also held senior HR roles in the financial services and ICT industries and led a number of organisational development and transformation initiatives.

Antony Fitzpatrick

Mr. Antony Fitzpatrick is Executive Vice President – Operations of the Company. Antony has a first class BSc in aeronautical engineering from Manchester University and an MSc in numerical computation from the University of Manchester Institute of Science and Technology. Antony joined Vectura from Baxter where he had worked since 1999, having been responsible for global supply chain and most recently VP manufacturing and supply chain for EMEA. This role included operations with 24 manufacturing sites, production values worth over $1.5bn, 9,000 employees and capex of over $100m. His Baxter experience includes operating in both a pharma product environment and in product device and pure medical device operations. Prior to working at Baxter he worked in various manufacturing and logistics roles for Ingram Micro (IT technology), Exel Logistics, Coopers and Lybrand and Mobil Oil.

Roger Heerman

Mr. Roger Heerman is Executive Vice President - Commercial and Business Development of the Company. Roger Heerman joined Vectura in 2010 and was appointed to the Executive Leadership Team in 2013. Experience and expertise Prior to joining Vectura, Roger gained extensive US and international commercialisation experience in a number of senior roles, including vice president sales and marketing of the US publicly held company Critical Therapeutics, Inc. and vice president, director of client service at McK Healthcare. At Critical Therapeutics, he was responsible for the build-out of the commercial infrastructure and the launch of ZYFLO CRR in the US. At McK Healthcare, Roger supported the launch and repositioning efforts of numerous US and global brands, including UCB’s NeuproR for Parkinson’s disease and IROKO’s AggrastatR for acute coronary syndrome. Roger began his career in the pharmaceutical industry as a sales representative in the respiratory division at GlaxoSmithKline. He received his BS from Babson College and his MBA from the F.W. Olin School of Business at Babson College.

David Lescuyer

Mr. David Lescuyer is Executive Vice President – Oral Business of the company. David joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC where he had been executive vice president – Oral business since April 2016. David, a French national, holds a BSc in mechanical engineering and an MBA from HEC Paris. David joined Skyepharma from Patheon Pharmaceuticals, where he was executive director and general manager, Patheon France, and more recently global VP, operational excellence. Prior to Patheon, David’s career included experience with Fareva, Cenexi and Catalent in senior operational and general management roles.

Gonzalo Miquel

Mr. Gonzalo De Miquel is Chief Medical Officer & Executive Vice President - Development of the company. Gonzalo De Miquel joined Vectura in February 2017. Gonzalo has highly relevant medical and product development experience ranging from pharmacovigilance and regulatory through to early and late stage clinical development and medical affairs. Prior to joining Vectura, Gonzalo was Vice President of Clinical Development at Astra Zeneca with responsibility for the overall strategy, organisation, resource assignment and project prioritisation across Astra Zeneca’s portfolio. Gonzalo trained in Internal medicine and Rheumatology practising for six years in Barcelona before moving into the pharmaceutical industry. Gonzalo has held senior positions including global clinical lead for respiratory autoimmunity at Boehringer working in early clinical development as well as the late-stage and launch of Spiriva in Spain and with Almirall as Director of Global Clinical Development, successfully leading their aclidinium franchise development through to FDA and EMA approvals in 2012 and previously as their head of Global Medical Affairs.

Geraldine Venthoye

Ms. Geraldine Venthoye is Executive Vice President - Pharmaceutical Development Appointment of the company. Dr Geraldine Venthoye joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where she had been executive vice president Pharmaceutical Development since 2013, having joined Skyepharma as Head of inhalation business unit in September 2003. Geraldine is a UK registered pharmacist and holds a doctorate degree in pharmaceutics from the University of London. Geraldine held senior CMC leadership and scientific roles in Inhale/ Nektar Therapeutics, San Carlos, California, US, and prior to this in the UK, held scientific positions in inhalation drug delivery at Vandsons Research and Norton Healthcare.

John Murphy

Mr. John Murphy is General Counsel, Company Secretary of the Company. John Murphy joined Skyepharma as General Counsel in March 2006 and was appointed as General Counsel and Company Secretary of Vectura in June 2016 following the merger. John is a lawyer with extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC. He is chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group. He holds a BSc in aeronautical engineering from Bristol University and is a qualified solicitor.

Per-Olof Andersson

Dr. Per-Olof Andersson is Non-Executive Director of the Company. Per-Olof is an expert in international research and development within the pharmaceuticals, bio-pharmaceuticals and speciality pharmaceutical industry and has considerable experience in respiratory therapeutic development. In 2011, Per-Olof retired from Almirall where he was executive director for R&D and a member of the board of directors. Prior to joining Almirall in 2006, Per-Olof had a distinguished international career at Pharmacia and Pfizer over a period of nearly 20 years. Since 2011, Per-Olof has been an independent consultant advising biotech and pharma companies. To support the 2018 Corporate Governance Code, Per-Olof has been appointed as the nominated Non-Executive Director who will oversee engagement between the Board and the workforce.

Juliet Thompson

Ms. Juliet Thompson is Non-Executive Director of the Company. Juliet has a BSc in economics and is a chartered accountant. She has spent over 20 years actively involved in the life sciences sector working as an investment banker and strategic advisor to healthcare companies in Europe. She headed up the European healthcare team at Stifel (formerly Oriel) and prior to this was a founding partner of Code Securities, a healthcare investment banking boutique which was acquired by Nomura, later forming Nomura Code. Current external appointments Juliet is deputy chairman of Nexstim plc, a Nasdaq-listed Finnish medical technology company, and sits on the boards of Novacyt S.A., a French company whose shares are admitted to trade on AIM, and GI Dynamics, Inc., a US headquartered, Australian stock exchange listed company. She chairs the audit committee of each of these three companies. She was appointed a director and remuneration committee chair of Scapa Group plc on 21 January 2019, and also as a member of both its audit and risk and nomination committees.

Thomas Werner

Mr. Thomas Werner is Non-Executive Director of the Company. Thomas Werner was appointed to the Board of Skyepharma as a Non-Executive Director in May 2009 and joined the Board of Vectura following the merger in June 2016. He holds a degree in chemistry from the University of Göttingen. Thomas Werner has over 30 years of experience in the pharmaceutical industry, previously as senior vice president of GlaxoSmithKline where he was managing director for Germany and also co-ordinated its European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. He has held various non-executive positions including Riemser Pharma GmbH and New Oncology AG. Beside his business responsibilities he has previously served for many years on the board of trustees of the Paul Ehrlich Foundation and the Robert Koch Foundation and was a director of the American Chamber of Commerce in Germany representing healthcare companies. Thomas is chairman of Fertin Pharma, a Danish medicated chewing gum company, and sits on the boards of Basilea Pharmaceutica Ltd and BSN Medical. He is chairman of the investor advisory committee of the Seventure (France) Health for Life capital investment fund.

Susan Foden

Dr. Susan Elizabeth Foden, Ph.D. is Senior Independent Non-Executive Director of the Company. She joined the Board of Vectura as a Non-Executive Director in January 2007. She chairs the Remuneration Committee and is a member of the Audit and Nomination Committees. She holds a number of Non-Executive Directorships with both public and private companies in the biotech and healthcare field, including Source Bioscience plc, Cizzle Biotechnology Ltd, BerGenBio AS and Evgen Ltd. Prior to this Susan Foden held positions in venture capital and UK biotech companies. From 2000 to 2003 she was an Investor Director with the London-based venture capital firm Merlin Biosciences Limited, and was Chief Executive Officer of the technology transfer company Cancer Research Campaign Technology Ltd from 1987 to 2000. She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.

Kevin Matthews

Dr. Kevin Matthews is Independent Non-Executive Director of the Company. Kevin has more than 20 years' experience in senior management roles in the chemical, technology and pharmaceutical sectors. He has significant marketing, strategy and management expertise and was, until the end of 2018, Executive Chair of Itaconix plc, an AIM-listed polymers business, having successfully led the organisation as Chief Executive Officer. A Fellow of the Royal Society of Chemistry, Kevin has a strong technical background and has previously held CEO roles at technology companies including Isogenica, a privately-held antibody drug discovery company and Oxonica plc, an advanced materials business. Prior to this he held leadership roles in multinational chemical companies Rhodia S.A, Albright & Wilson plc and ICI. Kevin is currently a Non-Executive Director on the Board of FTSE SmallCap performance materials business, Low & Bonar plc, where he chairs the Remuneration Committee. He is also an advisor to the Board of the privately held specialty chemicals company, Scott Bader. He served as a Non-Executive Director and Remuneration Committee chair of Elementis plc, a FTSE 250 specialty chemicals business from 2005 to 2014. He also served as a Non-Executive Director of Cellectricon AB, a Swedish biotechnology company dedicated to drug discovery and research in the areas of chronic pain and neurodegenerative disease, from 2011 to 2014.

Neil Warner

Mr. Neil William Warner is Non-Executive Independent Director of the Company. He joined the Board of Vectura as Non-Executive Director in February 2011. Neil brings significant financial and leadership experience in multinational listed companies. He was finance director at Chloride Group plc, a position he held for 14 years until the company’s acquisition by Emerson Electric. Prior to this, Neil spent six years at Exel plc (formerly Ocean Group plc and acquired by DHL/Deutsche Post in December 2005), where he held a number of senior posts in financial planning, treasury and control. He has also held senior positions in Balfour Beatty plc (formerly BICC Group plc), Alcoa and PricewaterhouseCoopers and was a non-executive director of Dechra Pharmaceuticals plc, where he was the senior independent director and chair of the audit committee. Neil was formerly the non-executive chairman of Enteq Upstream plc, a specialist reach and recovery products and technologies provider to the upstream oil and gas services market. Current external appointments Neil is senior independent director and audit committee chair of Trifast plc, a global leader in design, technology and manufacturing of industrial fasteners for the automotive and technology sectors. He is also a non-executive director, chair of the audit committee and member of the remuneration committee of Directa Plus plc which floated on AIM in May 2016. Directa Plus is one of the world’s largest producers of graphene-based materials, marketed under its “Graphene Plus” (G+) brand, which can be used by third parties in a wide variety of industrial and commercial applications.

Anne Whitaker

Ms. Anne Whitaker has been appointed as Independent Non-Executive Director of the Company., with effect from 1 June 2018. Experience and expertise She has more than 25 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech and speciality pharma companies. She has significant experience in the US respiratory sector and was, until recently, serving as president and chief executive officer of KNOW Bio, LLC and its wholly owned subsidiary, Novoclem Therapeutics, Inc. Previously, Anne was executive vice president and company group chairman at Valeant Pharmaceuticals. Prior to that, Anne served as president and chief executive officer of Synta Pharmaceuticals, now part of Madrigal Pharmaceuticals, Inc. She also served as president, North America pharmaceuticals at Sanofi, and held several commercial leadership roles at GlaxoSmithKline. Current external appointments Anne is currently a director and CEO of Dance Biopharma Holdings Inc., an independent director of Cree, Inc., a NASDAQ traded company, and an independent director of Mallinckrodt plc. She is also a trustee for the University of North Alabama.

Elizabeth Knowles